JP2018158946A - チオレドキシンを含有する皮膚外用剤組成物 - Google Patents
チオレドキシンを含有する皮膚外用剤組成物 Download PDFInfo
- Publication number
- JP2018158946A JP2018158946A JP2018131829A JP2018131829A JP2018158946A JP 2018158946 A JP2018158946 A JP 2018158946A JP 2018131829 A JP2018131829 A JP 2018131829A JP 2018131829 A JP2018131829 A JP 2018131829A JP 2018158946 A JP2018158946 A JP 2018158946A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- thioredoxin
- composition
- effect
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 108060008226 thioredoxin Proteins 0.000 title claims abstract description 50
- 102000002933 Thioredoxin Human genes 0.000 title claims abstract description 48
- 229940094937 thioredoxin Drugs 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000002537 cosmetic Substances 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 43
- 239000011148 porous material Substances 0.000 abstract description 15
- 210000002374 sebum Anatomy 0.000 abstract description 15
- 230000017531 blood circulation Effects 0.000 abstract description 14
- 230000006872 improvement Effects 0.000 abstract description 13
- 230000008602 contraction Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 63
- 239000002552 dosage form Substances 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 13
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 6
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 241000235070 Saccharomyces Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229960003473 androstanolone Drugs 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010050808 Procollagen Proteins 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000002985 plastic film Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000036570 collagen biosynthesis Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 101000954195 Homo sapiens Protein VAC14 homolog Proteins 0.000 description 1
- 101000852559 Homo sapiens Thioredoxin Proteins 0.000 description 1
- 101710116034 Immunity protein Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 description 1
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- NVKAWKQGWWIWPM-BPBNVRBRSA-N [14C@@H]12CC[C@H](O)[C@@]1(C)CC[C@H]1[C@H]2CC[C@H]2CC(=O)CC[C@]12C Chemical compound [14C@@H]12CC[C@H](O)[C@@]1(C)CC[C@H]1[C@H]2CC[C@H]2CC(=O)CC[C@]12C NVKAWKQGWWIWPM-BPBNVRBRSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000056461 human TXN Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- -1 skin Substances 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000008326 skin blood flow Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
- C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
- C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
- C12Y108/04—Oxidoreductases acting on sulfur groups as donors (1.8) with a disulfide as acceptor (1.8.4)
- C12Y108/0401—Adenylyl-sulfate reductase (thioredoxin) (1.8.4.10)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本発明の組成物の効能を実験するためのチオレドキシンは、株式会社ファーマフーズ(〒615−8245、京都府京都市西京区御陵大原1−49)のTRX日本酒エキス〔サッカロミケス発酵物(Saccharomyces Ferment)〕であり、チオレドキシンの含量は、4mg/1gである。
下記表1の組成に従い、通常の方法により栄養クリームを製造した(単位:重量%)。
チオレドキシンが皮膚の保湿力の増加に及ぼす効果を測定するために、前記剤形例1および比較剤形例1を用い、下記のようにして評価した。
チオレドキシンの角質形成細胞の分化促進効果を調べるために、下記のように角質形成細胞の分化時に生成される角化膜(CE:Cornified Envelop)の量を、吸光度を用いて測定した。
チオレドキシンが肌の損傷により損傷された肌のバリア機能の修復に及ぼす効果を測定するために、下記の実験を行った。成人男女10名の上腕をテープストリッピング(Tape Stripping)法を用いて肌のバリアに損傷を与え、それぞれ下記表4の組成に従い製造した剤形例2および比較剤形例2の2つの群を塗布しながら7日間1日につき1回ずつ経皮水分損失量(TWEL)の修復度をポータブル水分蒸散計バポメーター(Vapometer)(デルフィン・テクノロジーズ社製、フィンランド)を用いて測定し且つ比較した。ここで、比較剤形例2は陰性対照群であり、ビヒクル(展色剤)である。実験結果は、下記表5に示す。表5は、バリア損傷前と、バリア損傷後の剤形例2および比較剤形例2の処理前との違いを、100%を基準として比較したものである。
本発明に係る化粧料組成物の肌の血液循環促進効果を評価するために、レーザードップラー血流計(LDPI:Laser Doppler Perfusion Imager)を用いて肌における血液循環の度合いを測定した。レーザードップラー血流計(LDPI)は、肌における血液循環を測定する機器として広く知られており、現在用いられている器機であり、肌の毛細血管における血液の速度および量だけではなく、小動脈と小静脈における流れまで測定可能な非常に敏感な機器である。
前記剤形例1および比較剤形例1の肌トーンの改善効果を調べるために、30名の被験者にそれぞれ使用(1日につき夕方に1回塗布、合計1週間)させた後、コスメティック用全顔撮影装置フェイシャルステージ(Facial Stage)DM−3(モリテックス社製、日本)を用いて肌トーンの改善度を評価した。肌トーンの改善率は、肌の明度および色彩の測定値で判断し、その結果を下記表7に示す。明度および色彩の変化値が大きくなればなるほど、肌トーンが改善されたことを意味する。
1.コラーゲン生合成の促進を通じた毛穴の縮小効果
本発明に係るチオレドキシンのコラーゲン生合成の促進効果をTGF−βと比較して測定した。まず、繊維芽細胞(fibroblast)を24ウェルに1ウェル当たりに105個ずつ播種して約90%生長するまで培養した。これを無血清のダルベッコ改変イーグル培地(DMEM)において24時間培養した後、無血清培地に溶かした本発明のチオレドキシンとTGF−βをそれぞれ10ng/mlずつ処理し、CO2培養器において24時間培養した。これらの上澄み液を取ってプロコラーゲン型(I)のELISAキット〔procollagen type(I)〕を用いてプロコラーゲンの増減有無を調べてみた。その結果を下記表8に示し、コラーゲンの合成能は、非処理群を100にして比較した。
剤形例1および比較剤形例1の毛穴の縮小効果を調べるために、下記のようにして評価を行った。毛穴が大きい被験者男女20名を選定して10名ずつ2つの群に分け、各群別に顔に剤形例1および比較剤形例1の栄養クリームをそれぞれ4週間毎日塗布させた。毛穴の縮小効果に対する判定は、実験前と4週後の写真を撮って専門家の目視評価により行われた。その結果を、下記表9に示す(評価等級:0−全く縮小されていない、5−非常に縮小されている)。
1. 5α−リダクターゼ活性の抑制を通じた肌の過分泌の抑制効果
5α−リダクターゼ活性の抑制効果を確認するために、HEK293−5αR2細胞において[14C]テストステロンが[14C]ジヒドロテストステロン(DHT:dihydrotestosterone)に変換される割合を測定した。HEK293細胞にp3xFLAG−CMV−5αR2を形質感染させて24ウェルプレートに1ウェル当たりに2.5×105の細胞を入れて培養した(Park et al.,2003,JDS.Vol.31,pp.191−98)。翌日に酵素基質および阻害剤が添加された新たな培地に交換した。培地の基質としては、0.05μCi[14C]テストステロン(アマシャム・ファルマシア・バイオテク社製、英国)を用いた。
転換率[%] =[〔ジヒドロテストステロン(DHT)領域における放射能〕/総放射能]×100
阻害率[%] ={(対照群の転換率−試験物質の転換率)/対照群の転換率}×100
前記剤形例1および比較剤形例1の皮脂分泌の抑制効果を調べるために、下記のようにして評価を行った。皮脂分泌が多いと感じる被験者男女30名を選定して指定された部位に剤形例1および比較剤形例1の栄養クリームを4週間毎日塗布させた。皮脂減少の効果に対する判定は、皮脂量測定器〔セブメーター(Sebumeter)SM810、C+Kエレクトロニック社製、ドイツ〕を用いて2週間および4週間経過後の平均皮脂減少率(%)をそれぞれ測定し、その結果を下記表11に示す。
Claims (4)
- チオレドキシンからなる有効成分を含有する経皮水分損失抑制用皮膚外用剤組成物。
- チオレドキシン、プロピレングリコール及び水からなる混合物を含有する経皮水分損失抑制用皮膚外用剤組成物。
- 前記チオレドキシンは、組成物の総重量に対して1〜50重量%の量で含有されることを特徴とする請求項1又は2に記載の経皮水分損失抑制用皮膚外用剤組成物。
- 化粧料組成物であることを特徴とする請求項1又は2に記載の経皮水分損失抑制用皮膚外用剤組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0127891 | 2012-11-13 | ||
KR1020120127891A KR102026800B1 (ko) | 2012-11-13 | 2012-11-13 | 티오레독신을 함유하는 피부 외용제 조성물 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015541695A Division JP2015536979A (ja) | 2012-11-13 | 2013-11-13 | チオレドキシンを含有する皮膚外用剤組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018158946A true JP2018158946A (ja) | 2018-10-11 |
JP6823014B2 JP6823014B2 (ja) | 2021-01-27 |
Family
ID=50731421
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015541695A Pending JP2015536979A (ja) | 2012-11-13 | 2013-11-13 | チオレドキシンを含有する皮膚外用剤組成物 |
JP2018131829A Active JP6823014B2 (ja) | 2012-11-13 | 2018-07-11 | チオレドキシンを含有する皮膚外用剤組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015541695A Pending JP2015536979A (ja) | 2012-11-13 | 2013-11-13 | チオレドキシンを含有する皮膚外用剤組成物 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20150250700A1 (ja) |
JP (2) | JP2015536979A (ja) |
KR (1) | KR102026800B1 (ja) |
CN (2) | CN104684568A (ja) |
WO (1) | WO2014077568A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3949980A1 (en) * | 2020-08-04 | 2022-02-09 | Vassiliki Griva | Compositions for the treatment of atopic dermatitis containing ozonated oils and natural antioxidant agents |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016088905A (ja) * | 2014-11-07 | 2016-05-23 | 健治 椛島 | 上皮又は粘膜に投与される組成物 |
JP2016216436A (ja) * | 2015-05-18 | 2016-12-22 | 株式会社ファンケル | 皮膚粘弾性向上剤 |
KR102598485B1 (ko) * | 2016-06-27 | 2023-11-06 | (주)아모레퍼시픽 | 피부 항산화 조성물 |
CN107510624A (zh) * | 2017-08-24 | 2017-12-26 | 广州聚注通用技术研究院有限公司 | 一种吸附膜 |
JP7292058B2 (ja) * | 2019-03-04 | 2023-06-16 | 花王株式会社 | ステロイドホルモンの調製又は定量方法 |
CN115778837B (zh) * | 2022-11-21 | 2024-04-02 | 安徽品赫生物科技有限公司 | 一种协同增效的亮肤修护冻干粉及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0912471A (ja) * | 1995-06-29 | 1997-01-14 | Noevir Co Ltd | 皮膚外用剤 |
JP2001163757A (ja) * | 1999-12-08 | 2001-06-19 | Noevir Co Ltd | 皮膚外用剤 |
JP2002037709A (ja) * | 2000-07-24 | 2002-02-06 | Noevir Co Ltd | 皮膚外用剤 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU611421B2 (en) * | 1987-02-23 | 1991-06-13 | Shiseido Company Ltd. | Percutaneous absorption promoter and dermatologic preparation for external use |
US6555116B1 (en) * | 1991-10-12 | 2003-04-29 | Regents Of The University Of California | Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin |
DE10305965A1 (de) * | 2003-02-12 | 2004-08-26 | Beiersdorf Ag | Kosmetische und/oder dermatologische Zubereitung |
KR100585269B1 (ko) | 2004-12-31 | 2006-05-30 | 고려대학교 산학협력단 | Halobacterium salinarum에서 분리된 항산화 활성을 갖는 티오레독신 |
FR2885522B1 (fr) * | 2005-05-13 | 2020-01-10 | Sederma | Composition cosmetique ou dermopharmaceutique contenant de la teprenone |
JP2007037709A (ja) * | 2005-08-02 | 2007-02-15 | Sanyo Product Co Ltd | 遊技機 |
CN1951383A (zh) * | 2005-10-17 | 2007-04-25 | 美国安乃仁生命科技公司 | 稳定化含儿茶素医药及化妆品用组合物 |
GB0524884D0 (en) * | 2005-12-06 | 2006-01-11 | Syngenta Ltd | Improvements in or relating to organic compounds |
JP5279209B2 (ja) * | 2006-06-27 | 2013-09-04 | ロート製薬株式会社 | 皮膚外用剤 |
TWI392515B (zh) * | 2006-06-27 | 2013-04-11 | Rohto Pharma | Skin topical composition |
JP2011032195A (ja) * | 2009-07-31 | 2011-02-17 | Kracie Home Products Ltd | 老化防止化粧料 |
US20110160144A1 (en) * | 2009-12-28 | 2011-06-30 | Perricone Nicholas V | Topical Acyl Glutathione Formulations |
-
2012
- 2012-11-13 KR KR1020120127891A patent/KR102026800B1/ko active IP Right Grant
-
2013
- 2013-11-13 US US14/431,853 patent/US20150250700A1/en not_active Abandoned
- 2013-11-13 WO PCT/KR2013/010256 patent/WO2014077568A1/ko active Application Filing
- 2013-11-13 CN CN201380048674.2A patent/CN104684568A/zh active Pending
- 2013-11-13 JP JP2015541695A patent/JP2015536979A/ja active Pending
- 2013-11-13 CN CN201810799156.9A patent/CN108904319A/zh active Pending
-
2016
- 2016-12-21 US US15/386,943 patent/US20170100320A1/en not_active Abandoned
-
2018
- 2018-07-11 JP JP2018131829A patent/JP6823014B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0912471A (ja) * | 1995-06-29 | 1997-01-14 | Noevir Co Ltd | 皮膚外用剤 |
JP2001163757A (ja) * | 1999-12-08 | 2001-06-19 | Noevir Co Ltd | 皮膚外用剤 |
JP2002037709A (ja) * | 2000-07-24 | 2002-02-06 | Noevir Co Ltd | 皮膚外用剤 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3949980A1 (en) * | 2020-08-04 | 2022-02-09 | Vassiliki Griva | Compositions for the treatment of atopic dermatitis containing ozonated oils and natural antioxidant agents |
Also Published As
Publication number | Publication date |
---|---|
US20150250700A1 (en) | 2015-09-10 |
JP6823014B2 (ja) | 2021-01-27 |
WO2014077568A1 (ko) | 2014-05-22 |
KR20140060928A (ko) | 2014-05-21 |
JP2015536979A (ja) | 2015-12-24 |
CN108904319A (zh) | 2018-11-30 |
US20170100320A1 (en) | 2017-04-13 |
KR102026800B1 (ko) | 2019-09-30 |
CN104684568A (zh) | 2015-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6823014B2 (ja) | チオレドキシンを含有する皮膚外用剤組成物 | |
KR101695002B1 (ko) | 프로판노이드 유도체를 함유하는 피부 외용제 조성물 | |
US20130018020A1 (en) | Inhibitor for melanin, and cosmetic composition containing same | |
JP7309620B2 (ja) | 皮膚及び/又は粘膜を水和させるためのネフェリウム・ラパセウム(nephelium lappaceum)の果皮の抽出物の使用 | |
JP5944896B2 (ja) | コウゾ抽出物を含有する組成物 | |
CN113164797B (zh) | 聚伞岩蔷薇提取物的新型化妆品和皮肤病学用途 | |
KR20130035325A (ko) | 차나무 뿌리 유래 사포닌을 함유하는 피부 외용제 조성물 | |
US20180318356A1 (en) | Dermatological and cosmetic treatments using mesenchymal stem cells | |
JP2013155174A (ja) | タンゲレチン及びegcgを含有する皮膚外用剤組成物 | |
KR101779523B1 (ko) | 플라보노이드 유도체를 함유하는 화장료 조성물 | |
KR102286679B1 (ko) | 효소 처리된 차나무 뿌리 유래 사포닌 분획물을 함유하는 피부 외용제 조성물 | |
KR20120139222A (ko) | 탄시논ⅱa를 유효성분으로 함유하는 피부 외용제 조성물 | |
KR20090029536A (ko) | 콜라겐 합성 촉진용 조성물 및 이를 포함하는 화장품 | |
JPH10212225A (ja) | 抗シワ剤 | |
US11110117B2 (en) | Skin preparation composition for external use containing complex hyaluronic acid | |
KR20130115566A (ko) | 두족류 추출물 및 발효추출물을 함유하는 피부 화장료 | |
KR20120139223A (ko) | 크립토탄시논을 유효성분으로 함유하는 피부 외용제 조성물 | |
KR100528033B1 (ko) | 4-하이드록시-5-메톡시-4-[2-메틸-3-(3-메틸-2-부테닐)-2-옥시란닐]-1-옥사스피로[2,5]옥탄-6-온을 함유한 아토피 피부염 치료용 약제학적 조성물 | |
KR102430512B1 (ko) | 릴린 및/또는 vegf-c의 생산 및/또는 활성 촉진제 및 이를 이용한 피부 외용제 | |
KR102202210B1 (ko) | 육두구 추출물, 히알루론산 및 세리신을 포함하는 수분 보습용 화장료 조성물 | |
KR20130095949A (ko) | 진세노사이드 f1을 함유하는 피부 외용제 조성물 | |
WO2023234345A1 (ja) | 米糠油不ケン化物濃縮物を含む皮膚外用剤 | |
KR102172355B1 (ko) | Rx 콤플렉스 에스를 함유하는 피부 피지 조절용 화장료 조성물 | |
JP6732495B2 (ja) | 皮脂分泌抑制用組成物 | |
KR20200064610A (ko) | 연옥가루를 유효성분으로 함유하는 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180712 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200303 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200603 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200901 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201208 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210107 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6823014 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |